Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
 
Feedback
Home
c19early.org COVID-19 treatment researchSelect treatment..Select..
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Cichorium intybus for COVID-19

Cichorium intybus has been reported as potentially beneficial for treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Sunita et al., Characterization of Phytochemical Inhibitors of the COVID-19 Primary Protease Using Molecular Modelling Approach, Asian Journal of Microbiology and Biotechnology, doi:10.56557/ajmab/2024/v9i28800
The objective of this research is to find an antiviral medication that would work against the SARS-CoV-2 virus. Using existing effective pharmaceuticals from various virus treatments will be an immediate qualifying strategy. Virtual screening of antiviral databases for possible therapeutic effect were used to identify favourable pharmacological compounds. In anti-CoV medication development, targeting the major protease (pdb id: 6LU7) is becoming more significant. This paper focuses on the In silico evaluation of proposed anti-Alzheimer activity. Including toxicity prediction, molinspiration, AdmetSAR predictions, and targeted docking investigations, the best therapeutic candidates have been offered. Based on Viber and Lipinski rules, 4 derivatives were chosen for bioactivity prediction and drug similarity score. The reference standard drugs for the comparison of molecular descriptors and docking were hydrochloroquine and remdesivir. Remdesivir is a well-known FDA-approved drug that slows viral reproduction by terminating its binding to the viral RNA-dependent RNA polymerase. Our proposed compounds share similarities with Remdesivir, and doxorubicin is another drug with anti- SARS-CoV-2 virus. For pharmacological targets including such enzymes, nuclear receptors, kinase inhibitors, G protein-coupled receptor (GPCR) ligands, and ion channel modulators, the bioactivity score of the compounds was predicted Apart from 4 compound, which has been found to get AdmetSAR toxicity or impact, all proposed compounds showed good blood-brain barrier (BBB) penetration, human intestinal absorption (HIA), and Caco-2 cell permeability in their ADMET predictions. Rutin and quercetin have a strong affinity to inhibit these proteins which cause SARS-CoV-2 virus. Our data provide evidence that therapy is effective and enhances oral bioavailability.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit